Diseases

Lilly wins EU backing for version of insulin drug

June 27, 2014
Bloomberg News
Lantus, which garnered $7.8 billion in sales for Paris-based Sanofi in 2013, loses patent protection in Europe in May next year.
More

Insurance changes put state's autism industry on edge

June 14, 2014
J.K. Wall
Indiana's autism therapists say their prospects are cloudy after the state’s largest health insurer, Anthem Blue Cross and Blue Shield, cut payments 40 percent and took a harder line on paying for therapy for school-age children.
More

Endocyte shares plunge 60 percent after drug trial is stopped

May 2, 2014
 Bloomberg News and IBJ Staff
Endocyte Inc.'s stock fell more than 60 percent in early trading Friday after the drug it’s developing with Merck & Co.’s backing failed to help patients in a trial for ovarian cancer.
More

Cancer treatment makes Endocyte premium takeover target

March 28, 2014
Bloomberg News
Now that Indiana-based Endocyte Inc.’s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry’s highest premiums on record.
More

Endocyte stock doubles after key approval in Europe

March 21, 2014
Bloomberg News, J.K. Wall
The stock price of Endocyte Inc. skyrocketed by as much as 130 percent Friday morning after the drug company got a thumbs up in Europe to market its first drug and received a new round of favorable clinical trial results.
More

Lilly diabetes drug wins backing from EU regulator

March 21, 2014
Bloomberg News
Indianapolis-based Lilly is expected to garner $518 million in annual sales from Jardiance by 2019, according to the average of five analyst estimates compiled by Bloomberg.
More

Lilly diabetes drug rejected by FDA over manufacturing issue

March 5, 2014
Bloomberg News
The Lilly-Boehringer drug empagliflozin is projected to reach sales of $295 million for Lilly in 2019, but it won't be able to sell it until issues are resolved at a German plant.
More

Indiana one of many states aiming to limit tanning

March 2, 2014
Associated Press
Lawmakers' efforts to crack down on the use of Indiana tanning beds this year are part of a national push to limit young people's exposure to risks that include skin cancer.
More

Lilly diabetes drug matches competitors' effectiveness

February 25, 2014
 IBJ Staff and Bloomberg News
The Indianapolis drugmaker said dulaglutide performed as well as Victoza, a best-selling drug for Type 2 diabetics made by Denmark-based Novo Nordisk. Analysts think dulaglutide could reach annual sales of $1.5 billion.
More

U.S. venture gathers drugmakers to take on major diseases

February 4, 2014
Bloomberg News
Eli Lilly and Co., Pfizer Inc. and eight other large drugmakers will partner with the U.S. government in a $230 million effort to identify new approaches to treat Alzheimer’s, diabetes, lupus and arthritis.
More

Three groups puzzled by woman's $7 million bequest

January 8, 2014
Associated Press
The organizations which include Indianapolis-based Hoosier Oncology Group have no idea why an Evansville teacher chose them as beneficiaries.
More

Pfizer, Teva reach deal to allow generic Viagra

December 18, 2013
Bloomberg News
Fifteen years after Pfizer Inc.’s Viagra changed the sexual equation for older men, the blockbuster impotence drug is set to become available in a less expensive generic form as early as 2017.
More

Lilly foe still testing Alzheimer's theory where others failed

December 12, 2013
Bloomberg News
Since 1998, there have been more than 100 attempts to develop an Alzheimer’s treatment, and all have failed. Such a product may generate as much as $5 billion annually for Merck, according to analysts
More

Lilly to spend another $700M in growing market for diabetes products

November 14, 2013
 IBJ Staff, Bloomberg News
The move includes a $45 million investment for Lilly's operations in Indianapolis, on top of $400 million in investments the company announced over the past two years.
More

Lilly, other drugmakers itching to find new psoriasis treatment

October 4, 2013
Bloomberg News
Psoriasis is linked to higher rates of heart disease and diabetes, and a third of patients also develop a form of arthritis. About 125 million people worldwide have the skin condition, including 7.5 million Americans.
More

Lilly bets quality over quantity will pay off in diabetes battle

September 24, 2013
Bloomberg News
Eli Lilly and Co. is counting on the quality of a diversified product portfolio over boosting its sales forces to grab a bigger slice of the $22 billion U.S. diabetes market, a difference in strategy to some of its rivals.
More

Anthem rolls out new bonus system for docsRestricted Content

September 21, 2013
J.K. Wall
The Indianapolis-based health insurer expects to pay, on average, $3.50 per month for every patient enrolled in one of Anthem’s commercial health plans.
More

Alzheimer’s targeted in $45M government study grant

September 18, 2013
Bloomberg News
Part of the funding will go to an existing study of drugs from Eli Lilly and Co. and others to see whether they can ward off the disease in people who inherited genes that predestine them to get Alzheimer's.
More

Lilly lung cancer drug raises patient survival in trial

August 13, 2013
Bloomberg News
If approved, the drug would be a potent boost to Lilly’s product portfolio. It would also mean a critical new therapy for a cancer that’s proven difficult to treat.
More

Roche to cut local jobs after diabetes-care sales plunge

August 5, 2013
J.K. Wall
Roche's diabetes care unit, which employs more than 900 in Indianapolis, suffered a 14-percent decline in revenue during the first half of 2013. Roche has reportedly put the unit up for sale.
More

Lilly drug for Alzheimer's gets limited Medicare coverage

July 8, 2013
Bloomberg News, Associated Press
Lilly officials said they will push ahead with the first-of-a-kind imaging chemical, despite the mostly negative ruling by Medicare officials.
More

Lilly wins patent lawsuit on J&J Alzheimer’s research

June 25, 2013
Bloomberg News
A patent held by J&J’s Janssen Alzheimer Immunotherapy Research & Development unit isn’t valid, Judge Richard Arnold said in a ruling in London Tuesday.
More

Lilly’s experimental diabetes drug helps patients lose weight

June 24, 2013
Bloomberg News
Lilly’s drug, if approved, may be a significant competitor to Novo Nordisk A/S’s Victoza, which generated $1.64 billion in 2012.
More

Lilly halts trial of experimental Alzheimers drug

June 14, 2013
The trial ended after participants showed abnormal liver biochemistry, the Indianapolis-based drugmaker said Thursday in a statement.
More

New law lets pharmacists provide pneumonia, HPV vaccines

June 13, 2013
 The Statehouse File
Starting July 1, pharmacists will be able to offer a much wider variety of immunizations to customers, in an effort from lawmakers to make health care more accessible.
More
Page  1 2 3 4 5 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. By Mr. Lee's own admission, he basically ran pro-bono ads on the billboard. Paying advertisers didn't want ads on a controversial, ugly billboard that turned off customers. At least one of Mr. Lee's free advertisers dropped out early because they found that Mr. Lee's advertising was having negative impact. So Mr. Lee is disingenous to say the city now owes him for lost revenue. Mr. Lee quickly realized his monstrosity had a dim future and is trying to get the city to bail him out. And that's why the billboard came down so quickly.

  2. Merchants Square is back. The small strip center to the south of 116th is 100% leased, McAlister’s is doing well in the outlot building. The former O’Charleys is leased but is going through permitting with the State and the town of Carmel. Mac Grill is closing all of their Indy locations (not just Merchants) and this will allow for a new restaurant concept to backfill both of their locations. As for the north side of 116th a new dinner movie theater and brewery is under construction to fill most of the vacancy left by Hobby Lobby and Old Navy.

  3. Yes it does have an ethics commission which enforce the law which prohibits 12 specific items. google it

  4. Thanks for reading and replying. If you want to see the differentiation for research, speaking and consulting, check out the spreadsheet I linked to at the bottom of the post; it is broken out exactly that way. I can only include so much detail in a blog post before it becomes something other than a blog post.

  5. 1. There is no allegation of corruption, Marty, to imply otherwise if false. 2. Is the "State Rule" a law? I suspect not. 3. Is Mr. Woodruff obligated via an employment agreement (contractual obligation) to not work with the engineering firm? 4. In many states a right to earn a living will trump non-competes and other contractual obligations, does Mr. Woodruff's personal right to earn a living trump any contractual obligations that might or might not be out there. 5. Lawyers in state government routinely go work for law firms they were formally working with in their regulatory actions. You can see a steady stream to firms like B&D from state government. It would be interesting for IBJ to do a review of current lawyers and find out how their past decisions affected the law firms clients. Since there is a buffer between regulated company and the regulator working for a law firm technically is not in violation of ethics but you have to wonder if decisions were made in favor of certain firms and quid pro quo jobs resulted. Start with the DOI in this review. Very interesting.

ADVERTISEMENT